Latest news 17/03/23 ( respected biotech press):-
"Merck's Keytruda plus TIGIT combo proves less effective than chemo in open-label lung cancer study"
Ahead of Keytruda’s patent cliff in 2028, Merck is trying to develop a variety of combination therapies that can extend the megablockbuster’s potential. But one of those combos just hit a snag, and it’s putting the company in damage control mode.
It was a phase 2 combo in NSCLC v chemo.........
Media, page-377
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $436.3M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 30.0¢ | $960.6K | 3.161M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 188729 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 46153 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |